肝硬化患者的咖啡因补充剂、炎症与肝功能：一项随机、安慰剂对照临床试验
Caffeine supplement, inflammation, and hepatic function in cirrhotic patients: A randomized, placebo- controlled, clinical trial.
作者信息
Abbas-Hashemi Seyed Ali, Yari Zahra, Hatami Behzad, Anushiravani Amir, Kolahdoozan Shadi, Zamanian Ali, Akbarzadeh Nadia, Hekmatdoost Azita
机构信息
Department of Clinical Nutrition and Dietetics, Faculty of Nutrition Sciences and Food Technology, National Nutrition and Food Technology Research Institute, Shahid Beheshti University of Medical Science, Tehran, Iran.
Department of Nutrition Research, National Nutrition and Food Technology Research Institute and Faculty of Nutrition Sciences and Food Technology, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
出版信息
Heliyon. 2024 Dec 11;11(1):e41138. doi: 10.1016/j.heliyon.2024.e41138. eCollection 2025 Jan 15.
AIM
We investigated the possibility of caffeine supplementation for managing the inflammation, and hepatic function in cirrhotic patients.
METHODS
In this randomized, double-blind, placebo-controlled trial, fifty patients with cirrhosis were randomly assigned to receive either caffeine supplement (400 mg), or placebo for eight weeks.
RESULTS
The results indicated a significant decrease in AST, platelets (P = 0.002), and PTT (P < 0.001), in the caffeine group compared to the placebo group. Also, caffeine supplementation resulted in a significant reduction in inflammatory biomarkers compared to placebo (p < 0.05). A significant improvement in liver indices including AST to platelet ratio index (APRI), (P < 0.001). Fibrosis 4 score (P < 0.001), and MELD score (P = 0.034)., was observed after 8 weeks caffeine supplementation.
CONCLUSION
The results of the present study indicated that daily supplementation of 400 mg caffeine in cirrhotic patients can significantly improve liver fibrosis and reduce inflammatory factors.The trial was registered at the Iranian Registry of Clinical Trials (Registration ID: IRCT20100524004010N34).
目的
我们研究了补充咖啡因对肝硬化患者炎症及肝功能的影响。
方法
在这项随机、双盲、安慰剂对照试验中，50例肝硬化患者被随机分为两组，分别接受咖啡因补充剂（400毫克）或安慰剂，为期8周。
结果
结果表明，与安慰剂组相比，咖啡因组的谷草转氨酶、血小板（P = 0.002）和部分凝血活酶时间（PTT，P < 0.001）显著降低。此外，与安慰剂相比，补充咖啡因导致炎症生物标志物显著降低（p < 0.05）。补充咖啡因8周后，观察到肝脏指标包括谷草转氨酶与血小板比值指数（APRI，P < 0.001）、纤维化4评分（P < 0.001）和终末期肝病模型（MELD）评分（P = 0.034）有显著改善。
结论
本研究结果表明，肝硬化患者每日补充400毫克咖啡因可显著改善肝纤维化并降低炎症因子。该试验已在伊朗临床试验注册中心注册（注册号：IRCT20100524004010N34）。
Zotero 插件